the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Official Title A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Principal Investigator Nanda, Rita
Brief Summary This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Gender All
Ages 18 Years
Enrollment 1000
Accepts Healthy Volunteers No
Lead Sponsor National Cancer Institute (NCI)NIH
Collaborator
Study Design
Study Phase Phase 3
Study Type Interventional
Contact Name Gary E. Goodman
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Estrogen Receptor Negative
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI